Shanghai Lymphoma Clinical Cohort
- Sponsor
- Ruijin Hospital
- Study ID
- NCT07285174
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cohort
- Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 16 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- No interventions need to be specified for this study — OTHERNo interventions need to be specified for this study
Study Details
The aim of this study is to prospectively collect clinical information on patients with lymphoma, and to explore the best therapeutic strategies in the real-world population.
Key Dates
- First listed
- Dec 16, 2025
- Start date
- Dec 18, 2025
- Status verified
- Dec 2025
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2029
Study Design
- Enrollment
- 1,000 participants (estimated)
Arms
- Arm: Shanghai Lymphoma Clinical CohortShanghai Lymphoma Clinical Cohort
Primary Outcome Measure
Progression Free Survival (PFS) [ Time Frame: Baseline up to data cut-off (up to approximately 1 year) ]
Central Contacts
- Weili Zhao, MD, PhD+862164370045
- Pengpeng Xu, MD+862164370045
Related Studies
- Bone Marrow Grafting for Leukemia and LymphomaEnrolling By Invitation · Stanford University · Stanford, California
- Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative DisordersRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerRecruiting · Barbara Ann Karmanos Cancer Institute · Detroit, Michigan
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruiting · UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina